Kava Interactions

Kava and alcohol both depress the central nervous system through GABAergic and other mechanisms, producing additive sedation and motor impairment. More importantly, both substances are hepatotoxic, and concurrent use significantly increases the risk of severe liver injury, including cases of fulminant liver failure requiring transplantation.

Kava carries a documented risk of hepatotoxicity and produces CNS depression, and combining it with fluoxetine raises the risk of additive sedation and liver injury. Kava also inhibits CYP2D6 and CYP3A4, the enzymes that metabolize fluoxetine, which can elevate fluoxetine levels and side effects.

Kava (Piper methysticum) has central nervous system depressant effects and a documented risk of hepatotoxicity, and combining it with sertraline raises the risk of additive sedation and liver injury. Sertraline itself is associated with hepatic adverse effects in a small subset of users, and stacking hepatotoxic agents is discouraged.

Kava contains kavalactones that potentiate GABA-A receptor binding, producing additive CNS depression when combined with alprazolam, a benzodiazepine that also enhances GABA-A activity. A published case report describes a 54-year-old man who became semi-comatose after taking alprazolam with kava for three days.

Kava's kavalactones bind GABA-A receptors and produce additive central nervous system depression when combined with diazepam, a long-acting benzodiazepine. Concurrent use is not recommended due to risk of excessive sedation, impaired coordination, and potential additive hepatotoxicity.